EUCTR2019-002665-35-DK进行中（未招募）1 期
16a-18F-fluor-17ß-estradiol PET/CT for detection of estrogen receptor positive liver metastases in breast cancer
Mikkel Holm Vendelbo0 个研究点目标入组 8 人开始时间: 2019年9月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients with known disseminated breast cancer
- •- Metastatic ER+ HER2- breast cancer with metastases in the liver, at least two separate foci visualised on CT
- •- Diagnostic CT performed in connection to clinical control
- •- Treatment with aromatase inhibitor and any additional treatments, or treatment with chemotherapy
- •- Postmenopausal status
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 4
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •- Treatment with Tamoxifen or Fulvestrant completed within 5 weeks prior to FES PET/CT
- •- ER- metastases
- •- Life expectancy less than three months
- •- Claustrofobia
- •- Pain which make it impossible to lie still in the scanner for 90 minutes
研究者
相似试验
招募中
不适用
FES (16a-[18F]-fluoro-17β-estradiol)-PET: Towards a new standard for staging of clinical stage II/III and recurrent, estrogen receptor positive (ER+) breast cancer? Pilot study to compare [18F]FES-PET and [18F]FDG-PET.Breast cancerNL-OMON50317Vrije Universiteit Medisch Centrum40
终止
早期 1 期
18F-FES PET/CT in Imaging Patients With Desmoid TumorsDeep Fibromatosis/Desmoid TumorFamilial Adenomatous PolyposisNCT02374931Vanderbilt-Ingram Cancer Center3
进行中（未招募）
1 期
FES (16a-[18F]-fluoro-17ß-estradiol)-PET: Towards a new standard to stage clinical stage II/III and recurrent, estrogen receptor positive (ER+) breast cancer? Pilot study to compare [18F]FES-PET and [18F]FDG-PET.Breast cancer.EUCTR2018-002013-35-NLVU University Medical Center40
终止
不适用
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted TherapyEstrogen Receptor PositiveRecurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7NCT02149173University of Washington29
进行中（未招募）
2 期
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted TherapyEstrogen Receptor PositivePrimary or Recurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7NCT04692103University of Washington2